S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML

Podobne zapisy

• S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
  od: Pau Montesinos, i wsp.
  Wydane: (2023-08-01)
• PB1779: FLT3-ITD MUTATION CHARACTERIZATION WITH CLASSICAL PCR METHODOLOGY VERSUS CAPTURE- AND AMPLICON-BASED NGS PLATFORMS: A PETHEMA NGS-AML PROJECT
  od: Cristina Bilbao, i wsp.
  Wydane: (2023-08-01)
• P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
  od: Mar Tormo, i wsp.
  Wydane: (2023-08-01)
• Validation of mutated <i>CEBPA</i> bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
  od: Esther Prados de la Torre, i wsp.
  Wydane: (2024-04-01)
• In Situ Use of Mining Substrates for Wetland Construction: Results of a Pilot Experiment
  od: Carmen Hernández-Pérez, i wsp.
  Wydane: (2024-04-01)